Genmab reports 38% of patients achieved ACR50 in HuMax-CD20 study to treat rheumatoid arthritis

By Lisa Kerner

Erie, Pa., March 21 - Genmab A/S released additional data from the HuMax-CD20 phase 1/2 study to treat patients with active rheumatoid arthritis.

Of the 26 patients receiving two doses of HuMax-CD20, 38% achieved ACR50 (American College of Rheumatology criteria for improvement) and 15% achieved ACR70.

Re-examination of the previously reported ACR20 data revealed that one responder in the 300 mg dose group received only one dose of HuMax-CD20.

As a result, 73% of patients treated with two doses of HuMax-CD20 achieved ACR20.

"During the conduct of this phase 1/2 study and the ongoing phase 2 study in [rheumatoid arthritis] we have reduced the side effects associated with the infusion by intensifying the pre-medication," chief operating officer Claus Moller said in the release.

"We believe that the safety profile of HuMax-CD20 in this patient population looks favorable compared to other therapies and that only very few patients will have problems tolerating the full dose planned. This is supported by the ongoing enrollment in the phase 2 study where 101 patients have received treatment with HuMax-CD20."

Genmab presented the data at the 10th Anniversary Inflammation and Immune Diseases, Drug Discovery and Development Summit in New Brunswick, N.J.

Genmab is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company is located in Copenhagen, Denmark.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.